MAPT and Lewy body dementia: Future studies on CSF α-synuclein and brain imaging may build on this and incorporate CSF Aβ42, T-tau and P-tau, and for example test if low CSF α-synuclein increases the risk for DLB-type pathology in subjects where other biomarkers strongly indicate AD.